TY - JOUR
T1 - Proceedings from the Second Haploidentical Stem Cell Transplantation Symposium-Haplo2014, San Francisco, California, December 4, 2014
AU - Al Malki, Monzr M.
AU - Horowitz, Mary
AU - Handgretinger, Rupert
AU - Leung, Wing
AU - Roy, Denis Claude
AU - Huang, Xiao Jun
AU - Fuchs, Ephraim
AU - Locatelli, Franco
AU - Blaise, Didier
AU - Mineishi, Shin
AU - Martelli, Massimo
AU - Miller, Jeffrey
AU - June, Carl
AU - Ai, Hui sheng
AU - Luznik, Leo
AU - Mavilio, Domenico
AU - Lugli, Enrico
AU - van den Brink, Marcel R.M.
AU - Champlin, Richard E.
AU - Ciurea, Stefan O.
N1 - Publisher Copyright:
© 2016 American Society for Blood and Marrow Transplantation.
PY - 2016/4/1
Y1 - 2016/4/1
N2 - Significant progress has been made over the past decade in haploidentical transplantation, with the development of novel methods to control intense alloreactive reactions generated in the major HLA-mismatched setting. Application of post-transplantation cyclophosphamide has gained worldwide acceptance as an effective and low-cost way to perform this type of transplantation, with outcomes now similar to those from HLA-matched unrelated donors. These advances have resulted in improved treatment-related mortality, whereas disease relapse has emerged as the most common cause of treatment failure. In addition, improvements in immunologic reconstitution after transplantation are much needed, not only in haploidentical transplantation but in all forms of stem cell transplantation. This symposium has focused on some of the most promising methods to control alloreactivity in this form of transplantation and application of cellular therapy to prevent disease relapse after transplantation, as well as understanding immunologic reconstitution and foreseeable approaches to improve immune recovery after transplantation.
AB - Significant progress has been made over the past decade in haploidentical transplantation, with the development of novel methods to control intense alloreactive reactions generated in the major HLA-mismatched setting. Application of post-transplantation cyclophosphamide has gained worldwide acceptance as an effective and low-cost way to perform this type of transplantation, with outcomes now similar to those from HLA-matched unrelated donors. These advances have resulted in improved treatment-related mortality, whereas disease relapse has emerged as the most common cause of treatment failure. In addition, improvements in immunologic reconstitution after transplantation are much needed, not only in haploidentical transplantation but in all forms of stem cell transplantation. This symposium has focused on some of the most promising methods to control alloreactivity in this form of transplantation and application of cellular therapy to prevent disease relapse after transplantation, as well as understanding immunologic reconstitution and foreseeable approaches to improve immune recovery after transplantation.
KW - Cellular therapy
KW - Haploidentical transplantation
KW - Immunologic reconstitution after transplantation
KW - Post-transplantation cyclophosphamide
KW - T cell depleted
UR - http://www.scopus.com/inward/record.url?scp=84960481145&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84960481145&partnerID=8YFLogxK
U2 - 10.1016/j.bbmt.2016.01.001
DO - 10.1016/j.bbmt.2016.01.001
M3 - Article
C2 - 26806585
AN - SCOPUS:84960481145
SN - 1083-8791
VL - 22
SP - 594
EP - 604
JO - Biology of Blood and Marrow Transplantation
JF - Biology of Blood and Marrow Transplantation
IS - 4
ER -